Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation and Depletion (2019 - 2024)

Allogene Therapeutics (ALLO) has disclosed Depreciation and Depletion for 6 consecutive years, with $3.6 million as the latest value for Q1 2024.

  • Quarterly Depreciation and Depletion rose 1.37% to $3.6 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $14.2 million through Mar 2024, up 0.97% year-over-year, with the annual reading at $14.2 million for FY2023, 0.67% down from the prior year.
  • Depreciation and Depletion hit $3.6 million in Q1 2024 for Allogene Therapeutics, up from $3.5 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $4.2 million in Q4 2021 to a low of $1.8 million in Q3 2020.
  • Historically, Depreciation and Depletion has averaged $2.9 million across 5 years, with a median of $3.5 million in 2023.
  • Biggest five-year swings in Depreciation and Depletion: skyrocketed 247.98% in 2020 and later fell 27.68% in 2022.
  • Year by year, Depreciation and Depletion stood at $1.8 million in 2020, then surged by 130.04% to $4.2 million in 2021, then dropped by 27.68% to $3.1 million in 2022, then grew by 13.33% to $3.5 million in 2023, then increased by 2.24% to $3.6 million in 2024.
  • Business Quant data shows Depreciation and Depletion for ALLO at $3.6 million in Q1 2024, $3.5 million in Q4 2023, and $3.6 million in Q3 2023.